Compass Pathways plc (Nasdaq: CMPS), a biotechnology company focused on accelerating patient access to evidence-based innovation in mental health, announced that management will attend the RBC Capital Markets Global Healthcare Conference on May 19-20, 2026 and will participate in a fireside chat on May 19 at 10:00am ET.
Event Details
A live audio webcast of the event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.
About Compass Pathways
Compass Pathways is motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. The company is pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 synthetic psilocybin treatment, which is potentially a first-in-class treatment.
COMP360 has received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD). Compass is headquartered in London, UK, with offices in New York in the US.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.cadillacnews.com/ap/business/compass-pathways-to-participate-in-rbc-capital-markets-global-healthcare-conference-on-may-19-20/article_1280670f-b688-5855-89a2-da306dccc9db.html